Drug Profile
Pemvidutide - Altimmune
Alternative Names: ALT-801- Altimmune; SP-1373; VPD-107Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Velocity Pharmaceutical Development
- Developer Altimmune; Velocity Pharmaceutical Development
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis; Obesity
- Phase I Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In the elderly, In volunteers, In adults) in Australia (SC, Injection)
- 30 Nov 2023 Efficacy and adverse events data from phase II MOMENTUM trial for Obesity released by Altimmune
- 26 Oct 2023 Pemvidutide - Altimmune receives Fast Track designation for Non-alcoholic steatohepatitis [SC,Injection] in USA